Whitehouse Laboratories is pleased and overly excited to announce that it has undergone its most recent Food and Drug Administration (FDA) inspection and received no observations and thus no form-483 was issued. The five day, GMP compliance inspection, as based upon 21CFR Parts 210 and 211, took place March 31st through April 6th and was granted NAI (no action indicated) status. The inspection covered all relevant areas of the strict Good Manufacturing Practice (GMP) quality system required by the regulatory agency. This represents the fifth FDA inspection in a row of Whitehouse Laboratories in a row resulting in no observable actions being taken; a true testament to the importance and diligence of the quality system in our work environment.

To READ THE COMPLETE PRWEB PRESS RELEASE PLEASE CLICK HERE…